Research
Molecular
Tirzepatide was evaluated for its effects on cardiovascular and diabetic kidney disease biomarkers in overweight and obese adults with type 1 diabetes over a period of 21 months.
Practitioners may consider tirzepatide for managing cardiovascular and kidney health in overweight and obese patients with type 1 diabetes.
StrongSupportsmedium confidence
We evaluated CVD and DKD biomarkers with off-label long-term (21 months) use of tirzepatide in OW/OB adults with T1D.
Why this rating
The study involves long-term treatment and evaluation of biomarkers.
Source
Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months
Subhash Vishal Garg et al. · Diabetes Technology & Therapeutics · 2025
DOI 10.1089/dia.2024.0481
otherCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →